Platelet Function Testing in Cardiovascular Diseases
2004; Lippincott Williams & Wilkins; Volume: 110; Issue: 19 Linguagem: Inglês
10.1161/01.cir.0000147228.29325.f9
ISSN1524-4539
Autores Tópico(s)Venous Thromboembolism Diagnosis and Management
ResumoHomeCirculationVol. 110, No. 19Platelet Function Testing in Cardiovascular Diseases Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBPlatelet Function Testing in Cardiovascular Diseases Alan D. Michelson, MD Alan D. MichelsonAlan D. Michelson From the Center for Platelet Function Studies, Departments of Pediatrics, Medicine, and Pathology, University of Massachusetts Medical School, Worcester, Mass. Originally published9 Nov 2004https://doi.org/10.1161/01.CIR.0000147228.29325.F9Circulation. 2004;110:e489–e493Case presentation 1: Mr F. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day. A platelet function test demonstrates that his platelets are "resistant" to aspirin. Should his treatment be changed?Case presentation 2:Mr K. is a 60-year-old man with unstable angina who takes aspirin, 81 mg/day, and clopidogrel, 75 mg/day. A platelet function test demonstrates that his platelets are "resistant" to clopidogrel. Should his treatment be changed?Normal Platelet FunctionPlatelets are small cells of great importance in thrombosis, hemorrhage, and inflammation.1 Formation of the hemostatic plug at sites of vascular injury is described in Figure 1. Platelets localize, amplify, and sustain the coagulant response at the injury site and release procoagulant platelet-derived microparticles. Platelets contain a variety of inflammatory modulators (eg, CD40 ligand [CD40L]) that are released on platelet activation. Download figureDownload PowerPointFigure 1. Steps in platelet plug formation. A, Before vascular injury, platelets are maintained in a resting state by endothelial inhibitory factors: prostacyclin (PGI2), nitric oxide (NO), and CD39. B, The platelet plug is initiated by the exposure of collagen and the local generation of thrombin. This causes platelets to adhere via collagen and von Willebrand factor (vWF) and spread. C, The platelet plug is extended as additional platelets are activated via the release of thromboxane A2 (TxA2), ADP, and other platelet agonists. Platelet-to-platelet aggregation is mediated primarily by activation of the platelet surface GP IIb/IIIa (integrin αIIbβ3; not shown). D, A fibrin meshwork helps to perpetuate and stabilize the platelet aggregate. Reprinted from reference 2 with permission from Elsevier.Platelet Function Testing in Cardiovascular DiseasesPlatelets have an increasingly well-defined critical role in coronary artery thrombosis3 and in other common cardiovascular diseases, including stroke, peripheral vascular disease, and diabetes mellitus.1 Although the role of platelets in thrombosis is well characterized, platelets may also have a role in the pathogenesis of the underlying atherosclerotic process.3 Platelet function tests have been studied in cardiovascular disease as a means to predict clinical outcomes and to monitor antiplatelet drugs. Table 1 summarizes these tests. TABLE 1. Platelet Function Tests in Cardiovascular DiseaseBasis of TestName of TestAdvantagesDisadvantagesReported to Predict Clinical OutcomesMonitoring of Aspirin*Monitoring of Thienopyridines*Monitoring of GP IIb/IIIa Antagonists*TRAP indicates thrombin receptor-activating peptide; VASP, vasodilator-stimulated phosphoprotein; CV, coefficient of variation; GPV, glycoprotein V; and RPFA, rapid platelet function analyzer (Accumetrics). For further information on these tests, see reference 1.*No published studies address the clinical effectiveness of altering therapy based on a laboratory finding of resistance to aspirin, clopidogrel, or GP IIb/IIIa antagonists.In vivo cessation of blood flow by platelet plugBleeding timeIn vivo test; physiologicalNonspecific; insensitive; high interoperator CV; can leave scarNoNoNoNoIn vitro cessation of high shear blood flow by platelet plugPFA-100Simple, rapid; low sample volume; high shear; no sample preparation; whole blood assayDependent on von Willebrand factor, hematocrit; no instrument adjustmentYes12,13,20YesNot recommendedNot recommendedShear-induced platelet adhesionIMPACT (cone and plate (let) analyzer, DiaMed)Simple, rapid; point-of-care; low sample volume; high shear; whole blood assayInstrument not yet widely availableNoUnder developmentUnder developmentNot recommendedPlatelet-to-platelet aggregationAggregometry (turbidometric)Historical gold standardPoor reproducibility; high sample volume; sample preparation; time consuming; expensiveYes18,21Yes (with arachidonic acid and ADP)Yes (with ADP)YesAggregometry (impedance)Whole blood assayHigh sample volume; sample preparation; time consuming; expensiveYes16Yes (with arachidonic acid and ADP)Yes (with ADP)YesVerifyNow (Ultegra RPFA)Simple, rapid; point-of-care; low sample volume; no sample preparation; whole blood assayNo instrument adjustmentYes19,22Yes (with arachidonic acid or propyl gallate cartridge)Yes (with pending ADP cartridge)Yes (with TRAP cartridge)Plateletworks (Helena Laboratories)Minimal sample preparation; whole blood assayNot well studiedNoNoYesYesActivation-dependent changes in platelet surfacePlatelet surface P-selectin, platelet surface activated GP IIb/IIIa, leukocyte-platelet aggregates (flow cytometry)Low sample volume; whole blood assaySample preparation; expensive; requires flow cytometer and experienced operatorYes5,6Yes (with arachidonic acid)Yes (with ADP)YesActivation-dependent signalingVASP phosphorylation state (flow cytometry)Directly dependent on clopidogrel's target, P2Y12; low sample volume; whole blood assaySample preparation; expensive; requires flow cytometer and experienced technicianNoNoYesNoActivation-dependent release from plateletsPlatelet-derived microparticles (flow cytometry)Low sample volume; whole blood assaySample preparation; expensive; requires flow cytometer and experienced technicianNoNoNoNoSerum thromboxane B2Directly dependent on aspirin's target, COX-1Indirect measure; not platelet specificNoYesNoNoUrinary 11-dehydrothromboxane B2Directly dependent on aspirin's target, COX-1Indirect measure; not platelet specific; dependent on renal functionYes17YesNoNoPlasma sCD40LMajority of plasma sCD40L is platelet-derivedSeparation of plasma can result in artifactual platelet activationYes10,11NoNoNoPlasma GPVPlatelet specificSeparation of plasma can result in artifactual platelet activation; reflects only thrombin-mediated platelet activationNoNoNoNoα-Granule constituents in plasma: platelet factor 4, β-thromboglobulin, soluble P-selectinReflect platelet secretionSeparation of plasma can result in artifactual platelet activation; plasma soluble P-selectin also originates from endothelial cellsNoNoNoNoUse of Platelet Function Tests to Predict Clinical OutcomesIn acute coronary syndromes and after coronary stenting, flow cytometric analysis of platelet activation–dependent markers predicts major adverse cardiac events (MACE).5 Increased platelet surface P-selectin is also a risk factor for silent cerebral infarction in patients with atrial fibrillation.6 However, circulating monocyte–platelet aggregates are a more sensitive marker of in vivo platelet activation than is platelet surface P-selectin in the clinical settings of stable coronary artery disease,7 human percutaneous coronary intervention,8 and acute myocardial infarction.8 Furthermore, circulating monocyte–platelet aggregates are an early marker of acute myocardial infarction.9 Measurement of plasma CD40L in the first 12 hours after the onset of ischemic symptoms in patients with unstable angina identifies a subgroup of patients that gains a much greater clinical benefit from abciximab treatment.10 High plasma concentrations of sCD40L may be associated with increased cardiovascular risk in apparently healthy women.11 In patients with stable angina, the Platelet Function Analyzer-100 (PFA-100; Dade Behring) closure time may predict the presence or absence of coronary artery stenoses at angiography, thereby potentially avoiding further diagnostic investigations.12 PFA-100 closure time may also be predictive of the severity of myocardial damage in acute myocardial infarction.13 In summary, although a number of studies have demonstrated that platelet function tests can predict MACE in cardiovascular diseases, none of these assays have been sufficiently studied in large clinical trials to become part of standard clinical care.Use of Platelet Function Tests to Monitor Antiplatelet DrugsAspirin reduces the odds of a serious arterial thrombotic event in high-risk patients by ≈25%.14 However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up.14 The failure of aspirin to prevent an arterial thrombotic event has been termed aspirin resistance. The failure of clopidogrel to prevent an arterial thrombotic event has been termed clopidogrel resistance. Similarly, the term GP IIb/IIIa antagonist resistance could be used. Because arterial thrombosis is multifactorial, an adverse arterial thrombotic outcome in a patient may often reflect treatment failure rather than resistance to an antiplatelet drug. Furthermore, patient noncompliance with aspirin, clopidogrel, or both is a frequent and hard-to-detect confounding problem. There is well-documented variability between patients (and "normal" volunteers) with regard to laboratory test responses to aspirin,15–20 thienopyridines,21 and GP IIb/IIIa antagonists.22 This variability in laboratory test response has also been termed "resistance" to antiplatelet agents. The key question is: Do laboratory tests of resistance to aspirin, clopidogrel, or GP IIb/IIIa antagonists predict clinical resistance to these drugs (ie, MACE)? Clinically meaningful definitions of aspirin, clopidogrel, and GP IIb/IIIa antagonist resistance can be based only on data linking drug-dependent laboratory tests to clinical outcomes in patients. Until such links are clearly established, MACE that occur despite an antiplatelet agent should not be termed drug resistance.AspirinAspirin irreversibly acetylates serine 530 of cyclooxygenase-1 (COX-1), resulting in the inhibition of thromboxane A2 release from platelets and prostacyclin from endothelial cells. Because platelets lack the synthetic machinery to generate significant amounts of new COX, aspirin-induced COX-1 inhibition lasts for the lifetime of the platelet. In contrast, endothelial cells retain their capacity to generate new COX and recover normal function shortly after exposure to aspirin. Possible mechanisms of aspirin resistance are listed in Table 2. There is evidence that MACE in the settings of acute coronary syndromes, stroke/transient ischemic attacks, and peripheral arterial disease can be predicted by the following in vitro tests of aspirin resistance: arachidonic acid– and ADP-induced platelet aggregation (turbidometric), ADP- and collagen-induced platelet aggregation (impedance), VerifyNow (Accumetrics), PFA-100, or urinary 11-dehydrothromboxane B2 (Figure 2A).15–20 However, in all of these studies, the number of MACE was low. TABLE 2. Possible Mechanisms of Aspirin and Clopidogrel ResistancePGH2 indicates prostaglandin H2.Bioavailability Noncompliance Underdosing Poor absorption (enteric-coated aspirin) Interference NSAID coadministration (competes with aspirin for serine 530 of COX-1) Atorvastatin (interferes with cytochrome P450-mediated metabolism of clopidogrel)Platelet function Incomplete suppression of thromboxane A2 generation (aspirin) Accelerated platelet turnover, with introduction into bloodstream of newly formed, drug-unaffected platelets Stress-induced COX-2 in platelets (aspirin) Increased platelet sensitivity to ADP and collagenSingle-nucleotide polymorphisms Receptors: P2Y12 H2 haplotype (clopidogrel), GP IIb/IIIa, collagen receptor, thromboxane receptor, etc Enzymes: COX-1, COX-2, thromboxane A2 synthase, etc (aspirin)Platelet interactions with other blood cells Endothelial cells and monocytes provide PGH2 to platelets (bypassing COX-1) and synthesize their own thromboxane A2 (aspirin)Other factors Smoking, hypercholesterolemia, etcRather than resistance, is it: Aspirin or clopidogrel response variability? Platelet response variability? Treatment failure (because arterial thrombosis is multifactorial)?Download figureDownload PowerPointFigure 2. Evidence that in vitro tests of resistance to antiplatelet drugs predict MACE. A, Aspirin resistance was determined by higher quartiles of urinary 11-dehydrothromboxane B2. P indicates trend of association. B, Clopidogrel resistance in study patients (Pts) was determined by quartiles of inhibition of ADP-induced platelet aggregation. C, Abciximab resistance was determined by VerifyNow 8 h after abciximab bolus but during infusion. Clinical follow-up was (A) 5 y, (B) 6 mo, and (C) 7 d. Reproduced with permission from Circulation.17,21,22 Copyright 2001, 2002, 2004, American Heart Association.ThienopyridinesThe thienopyridines clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi Aventis) and ticlopidine (Ticlid, Bristol-Myers Squibb/Sanofi Aventis) inhibit ADP from binding to its platelet surface P2Y12 receptor. Possible mechanisms of clopidogrel resistance are listed in Table 2. Matetzky et al found evidence that an in vitro test of clopidogrel resistance (ADP-induced platelet aggregation) predicts MACE, but the number of MACE was again low (Figure 2B).21 The P2Y12 H2 haplotype is reported to be associated with peripheral artery disease.23GP IIb/IIIa AntagonistsThe GP IIb/IIIa antagonists abciximab (ReoPro, Eli Lilly/Centocor), eptifibatide (Integrilin, Millennium Pharmaceuticals), and tirofiban (Aggrastat, Merck) inhibit fibrinogen from binding to platelet surface GP IIb/IIIa (integrin αIIbβ3), the final common pathway of platelet aggregation. Although the term resistance has not been used in the literature with regard to GP IIb/IIIa antagonists, there is substantial patient-to-patient variability in the degree of inhibition of platelet function by GP IIb/IIIa antagonists.22 Furthermore, there is evidence that an in vitro test of abciximab resistance (VerifyNow) predicts MACE (Figure 2C).22Treatment for Resistance to Antiplatelet AgentsAlthough some clinicians change treatment on the basis of platelet function testing,24 the correct treatment, if any, of aspirin resistance is unknown. Noncompliance should be considered. Increasing the dose of aspirin is unlikely to be helpful.14 Addition of a thienopyridine may be useful, with25 or without continued aspirin therapy. However, increased antiplatelet therapy may increase the risk of bleeding and other side effects. Most important, no published studies address the clinical effectiveness of altering therapy on the basis of a laboratory finding of resistance to aspirin, clopidogrel, or GP IIb/IIIa antagonists. In summary, therefore, other than in research trials, it is not currently appropriate to test for resistance in patients or to change therapy on the basis of such tests.DisclosureDr Michelson has received grant support from Accumetrics, Bristol-Myers Squibb/Sanofi-Aventis, Centocor/Eli Lilly, and Dade Behring.FootnotesCorrespondence to Alan D. Michelson, MD, Director, Center for Platelet Function Studies, Room S5-846, 55 Lake Ave N, Worcester, MA 01655. E-mail [email protected] References 1 Michelson AD, ed. Platelets. San Diego, Calif: Academic Press; 2002.Google Scholar2 Woulfe D, Yang J, Prevost N, et al. Signal transduction during the initiation, extension, and perpetuation of platelet plug formation. In: Michelson AD, ed. Platelets. San Diego, Calif: Academic Press; 2002: 197–213.Google Scholar3 Ruggeri ZM. Platelets in atherothrombosis. Nature Med. 2002; 8: 1227–1234.CrossrefMedlineGoogle Scholar4 Deleted in proof.Google Scholar5 Michelson AD, Barnard MR, Krueger LA, et al. Flow cytometry. In: Michelson AD, ed. Platelets. San Diego, Calif: Academic Press; 2002: 297–315.Google Scholar6 Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation. 1998; 98: 1721–1727.CrossrefMedlineGoogle Scholar7 Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte–platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998; 31: 352–358.CrossrefMedlineGoogle Scholar8 Michelson AD, Barnard MR, Krueger LA, et al. Circulating monocyte–platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001; 104: 1533–1537.CrossrefMedlineGoogle Scholar9 Furman MI, Barnard MR, Krueger LA, et al. Circulating monocyte–platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001; 38: 1002–1006.CrossrefMedlineGoogle Scholar10 Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003; 348: 1104–1111.CrossrefMedlineGoogle Scholar11 Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation. 2001; 104: 2266–2268.CrossrefMedlineGoogle Scholar12 Lanza GA, Sestito A, Iacovella S, et al. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation. 2003; 107: 1378–1382.LinkGoogle Scholar13 Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004; 110: 1392–1397.LinkGoogle Scholar14 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71–86.CrossrefMedlineGoogle Scholar15 Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993; 71: 397–403.CrossrefMedlineGoogle Scholar16 Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997; 78: 1003–1007.CrossrefMedlineGoogle Scholar17 Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002; 105: 1650–1655.LinkGoogle Scholar18 Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003; 41: 961–965.CrossrefMedlineGoogle Scholar19 Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004; 43: 1122–1126.CrossrefMedlineGoogle Scholar20 Grundmann K, Jaschonek K, Kleine B, et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003; 250: 63–66.CrossrefMedlineGoogle Scholar21 Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004; 109: 3171–3175.LinkGoogle Scholar22 Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation. 2001; 103: 2572–2578.CrossrefMedlineGoogle Scholar23 Fontana P, Gaussem P, Aiach M, et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation. 2003; 108: 2971–2973.LinkGoogle Scholar24 Pollack A. For some, aspirin may not help hearts. New York Times. July 20, 2004:F1.Google Scholar25 Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hsu H, Chan M, Armstrong P, Crescente M, Donikian D, Kondo M, Brighton T, Chen V, Chen Q, Connor D, Joseph J, Morel-Kopp M, Stevenson W, Ward C, Warner T and Rabbolini D (2022) A pilot study assessing the implementation of 96-well plate-based aggregometry (Optimul) in Australia, Pathology, 10.1016/j.pathol.2022.03.012, Online publication date: 1-Jun-2022. Behling‐Kelly E and Goggs R (2022) Thrombotic Disorders Schalm's Veterinary Hematology, 10.1002/9781119500537.ch91, (821-836), Online publication date: 22-Apr-2022. Bulla S, Badial P and Bulla C (2022) Canine Cancer Cells Activate Platelets via the Platelet P2Y12 Receptor, Journal of Comparative Pathology, 10.1016/j.jcpa.2022.01.002, 192, (41-49), Online publication date: 1-Apr-2022. Jeong C, Seo M, Chang O, Park J and Park C (2022) Assessment of coagulation function by thromboelastography in dogs with mitral valve insufficiency, Korean Journal of Veterinary Service, 10.7853/kjvs.2022.45.1.55, 45:1, (55-61), Online publication date: 30-Mar-2022. Loganathan J, Cohen A, Kaloupis G, Harris C, Chronopoulos A, James V, Hamilton J, Green S, Wallis A, Morgan S, Dauer R, Gilfillan C and Dear A (2022) A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study), Journal of Diabetes and its Complications, 10.1016/j.jdiacomp.2022.108188, 36:5, (108188), Online publication date: 1-May-2022. Cofer L, Barrett T and Berger J (2022) Aspirin for the Primary Prevention of Cardiovascular Disease: Time for a Platelet-Guided Approach, Arteriosclerosis, Thrombosis, and Vascular Biology, 42:10, (1207-1216), Online publication date: 1-Oct-2022.Lugo-Gavidia L, Burger D, Matthews V, Nolde J, Galindo Kiuchi M, Carnagarin R, Kannenkeril D, Chan J, Joyson A, Herat L, Azzam O and Schlaich M (2021) Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation, Hypertension, 77:6, (1825-1844), Online publication date: 1-Jun-2021. Leal Rato M, Diógenes M and Sebastião A (2021) Pharmacodynamics and Pharmacokinetics of Stroke Therapy Precision Medicine in Stroke, 10.1007/978-3-030-70761-3_5, (41-69), . Rafi U, Ahmad S, Bokhari S, Iqbal M, Zia A, Khan M, Roohi N and Dalmarco E (2021) Association of Inflammatory Markers/Cytokines with Cardiovascular Risk Manifestation in Patients with Endometriosis, Mediators of Inflammation, 10.1155/2021/3425560, 2021, (1-11), Online publication date: 31-Oct-2021. Huskens D, Li L, Florin L, de Kesel P, de Laat B, Roest M and Devreese K (2020) Flow cytometric analysis of platelet function to improve the recognition of thrombocytopathy, Thrombosis Research, 10.1016/j.thromres.2020.06.037, 194, (183-189), Online publication date: 1-Oct-2020. Ball S, Taylor R and McCollum C (2020) Resistance to Antiplatelet Therapy Is Associated With Symptoms of Cerebral Ischemia in Carotid Artery Disease, Vascular and Endovascular Surgery, 10.1177/1538574420947235, 54:8, (712-717), Online publication date: 1-Nov-2020. Hanrahan J, Seferovic J, Wakefield J, Wilson P, Chickering J, Jung J, Carlson K, Zimmer D, Frelinger A, Michelson A, Morrow L, Hall M, Currie M, Milne G and Profy A (2019) An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension, Diabetologia, 10.1007/s00125-019-05062-x, 63:4, (733-743), Online publication date: 1-Apr-2020. Kontos A, Willoughby S, Lushington K, Martin J, Wabnitz D, Dorrian J and Kennedy D (2020) Increased Platelet Aggregation in Children and Adolescents with Sleep-disordered Breathing, American Journal of Respiratory and Critical Care Medicine, 10.1164/rccm.201911-2229OC, 202:11, (1560-1566), Online publication date: 1-Dec-2020. Shao T, Cheng Y, Jin J, Huang L, Yang D, Luo C, Han Z, Wang Z, Ge W and Xu Y (2020) A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy, Journal of Clinical Neuroscience, 10.1016/j.jocn.2020.06.004, 78, (91-96), Online publication date: 1-Aug-2020. Lordkipanidzé M, Hvas A and Harrison P (2019) Clinical Tests of Platelet Function Platelets, 10.1016/B978-0-12-813456-6.00033-3, (593-608), . Ro J and Cho H (2019) Anti-platelet Effect of Black Tea Extract via Inhibition of TXA 2 in Rat , Biomedical Science Letters, 10.15616/BSL.2019.25.4.302, 25:4, (302-312), Online publication date: 31-Dec-2020. McFadyen J, Fernando H and Peter K (2019) Off-target drug effects on platelet function: Protecting an Achilles heel of drug development, Current Opinion in Toxicology, 10.1016/j.cotox.2019.09.004, 17, (9-17), Online publication date: 1-Oct-2019. Navaratnam K, Alfirevic A, Jorgensen A and Alfirevic Z (2018) Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia, European Journal of Obstetrics & Gynecology and Reproductive Biology, 10.1016/j.ejogrb.2017.12.052, 221, (144-150), Online publication date: 1-Feb-2018. Zhang Y, Ma X and Shi D (2015) Antiplatelet Effect of Active Components Derived from Chinese Herbal Medicine, Chinese Journal of Integrative Medicine, 10.1007/s11655-015-2297-9, 24:8, (632-640), Online publication date: 1-Aug-2018. Gawrys J, Gawrys K, Szahidewicz-Krupska E, Derkacz A, Mochol J and Doroszko A (2018) Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice, BioMed Research International, 10.1155/2018/7902081, 2018, (1-10), Online publication date: 2-Oct-2018. Ottani F, Femia E, Cattaneo M, Caravita L, Attanasio C and Galvani M (2018) Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial, International Journal of Cardiology, 10.1016/j.ijcard.2017.12.055, 255, (8-14), Online publication date: 1-Mar-2018. Kim J, Kaufman J, Patel S, Manco-Johnson M, Di Paola J and da Cruz E (2018) Antiplatelet Effect of Ketorolac in Children After Congenital Cardiac Surgery, World Journal for Pediatric and Congenital Heart Surgery, 10.1177/2150135118799041, 9:6, (651-658), Online publication date: 1-Nov-2018. Matus M, Vilos C, Cisterna B, Fuentes E and Palomo I (2018) Nanotechnology and primary hemostasis: Differential effects of nanoparticles on platelet responses, Vascular Pharmacology, 10.1016/j.vph.2017.11.004, 101, (1-8), Online publication date: 1-Feb-2018. (2018) Individual Compounds with Anti-Platelet Activity Isolated from Plant Sources Nutraceuticals and Human Blood Platelet Function, 10.1002/9781119375913.ch14, (231-246) Renga B and Scavizzi F (2017) Platelets and cardiovascular risk, Acta Cardiologica, 10.1080/00015385.2017.1281560, 72:1, (2-8), Online publication date: 2-Jan-2017. Mone F, Mulcahy C, McParland P and McAuliffe F (2017) Should we recommend universal aspirin for all pregnant women?, American Journal of Obstetrics and Gynecology, 10.1016/j.ajog.2016.09.086, 216:2, (141.e1-141.e5), Online publication date: 1-Feb-2017. Navaratnam K, Alfirevic Z, Pirmohamed M and Alfirevic A (2017) How important is aspirin adherence when evaluating effectiveness of low-dose aspirin?, European Journal of Obstetrics & Gynecology and Reproductive Biology, 10.1016/j.ejogrb.2017.10.004, 219, (1-9), Online publication date: 1-Dec-2017. Eichinger C, Fogelson A and Hlady V (2016) Functional assay of antiplatelet drugs based on margination of platelets in flowing blood, Biointerphases, 10.1116/1.4945305, 11:2, (029805), Online publication date: 1-Jun-2016. Tong L, Hosgood G, French A, Irwin P and Shiel R (2016) Platelet function and activation in Cavalier King Charles Spaniels with subclinical chronic valvular heart disease, American Journal of Veterinary Research, 10.2460/ajvr.77.8.860, 77:8, (860-868), Online publication date: 1-Aug-2016. Navaratnam K, Alfirevic A and Alfirevic Z (2016) Low dose aspirin and pregnancy: how important is aspirin resistance?, BJOG: An International Journal of Obstetrics & Gynaecology, 10.1111/1471-0528.13914, 123:9, (1481-1487), Online publication date: 1-Aug-2016. Lynch A, deLaforcade A, Meola D, Shih A, Bandt C, Guerrero N and Riccó C (2016) Assessment of hemostatic changes in a model of acute hemorrhage in dogs, Journal of Veterinary Emergency and Critical Care, 10.1111/vec.12457, 26:3, (333-343), Online publication date: 1-May-2016. Jain A, Graveline A, Waterhouse A, Vernet A, Flaumenhaft R and Ingber D (2016) A shear gradient-activated microfluidic device for automated monitoring of whole blood haemostasis and platelet function, Nature Communications, 10.1038/ncomms10176, 7:1, Online publication date: 1-Apr-2016. Quellec S, Bordet J, Negrier C and Dargaud Y (2017) Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response, Thrombosis and Haemostasis, 10.1160/TH15-11-0870, 116:10, (638-650), . Xu L, Hu X, Zhang S, Li J, Zhu
Referência(s)